Lilly and NCATS agree to drug screening partnership

Indianapolis-based pharmaceutical giant Eli Lilly signed a deal last week with the National Center for Advancing Translational Sciences (NCATS), providing for Lilly to screen over 3,800 currently approved and investigational new drugs for new potential therapeutic...

What’s coming for MDUFMA user fees?

An article published last week in MassDevice highlights the twists and turns (and resulting consensus) between FDA and medical device industry players in a series of February meetings targeting the medical device user fees program. Among the meetings’ accomplishments,...
Page 2 of 41234